ImmunoGen, Inc. Announces Results from Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial
June 02 2012 - 11:01PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company with a
proprietary Targeted Antibody Payload (TAP) technology, today
announced results from the trastuzumab emtansine Phase III EMILIA
trial conducted by Roche. Trastuzumab emtansine comprises
ImmunoGen's DM1 cancer cell-killing agent linked to the trastuzumab
antibody developed by Genentech, a member of the Roche Group, using
ImmunoGen’s method of attachment. It is in global development by
Roche under an agreement between ImmunoGen and Genentech. Roche
plans to apply this year for marketing approval of trastuzumab
emtansine in the US and Europe using EMILIA data.
The EMILIA 991-patient trial compares trastuzumab emtansine,
used alone, to lapatinib (Tykerb®) plus capecitabine (Xeloda®) for
the treatment of HER2-positive metastatic breast cancer that has
progressed after treatment with trastuzumab (Herceptin®) and a
taxane in any setting (early or metastatic disease).
Among the study findings reported are:
- Treatment with trastuzumab emtansine
significantly improved progression-free survival (PFS) compared to
treatment with lapatinib plus capecitabine, as assessed by an
independent review committee. Median PFS was 9.6 months compared to
6.4 months, respectively. The hazard ratio (HR) was 0.65 (p
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024